# NCT05555732 (NCT05555732)

> Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05555732
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Daiichi Sankyo
- Conditions: Metastatic Non Small Cell Lung Cancer
- Interventions: Datopotamab Deruxtecan; Pembrolizumab; Pemetrexed; Carboplatin; Cisplatin
- Enrollment: 1170
- Primary outcome: Progression-free Survival Based on Blinded Independent Central Review in All Randomized Participants
- Primary outcome: Progression-free Survival Based on Blinded Independent Central Review in All Randomized Participants who are TROP2 NMR positive
- Primary outcome: Overall Survival in All Randomized Participants
- Primary outcome: Overall Survival in All Randomized Participants who are TROP2 NMR positive

## Commentary we found

- YouTube: 14
- Podcasts: 9
- X threads: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct05555732

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05555732", "email": "<work email>"}; the inbox owner confirms by the emailed link.